Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of adult-onset Rheumatoid Arthritis (RA) for a duration of at least 6 months but not longer than 5 years~* positive Rheumatoid Factor (RF) and/or positive anti Cyclic Citrullinated Peptide (anti-CCP)~* active RA disease~* subjects must have failed at least one traditional Disease Modifying Anti-Rheumatic Drug (DMARD).~* subject is naïve to RA related biologics~Exclusion Criteria:~* a diagnosis of any other inflammatory arthritis~* history of infected joint prosthesis, or other significant infection~* known Tuberculosis (TB) disease or high risk of acquiring TB infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab pegol (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).